Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1

A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Initial results of the phase I trial: A New York Cancer Consortium

(2017) L. R. Silverman et al.   JOURNAL OF CLINICAL ONCOLOGY

Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation

(2010) W. C. Chou et al.   BLOOD

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Current and emerging therapies for acute myeloid leukemia

(2010) Tadeusz Robak et al.   CLINICAL THERAPEUTICS

FLT3 inhibition as a targeted therapy for acute myeloid leukemia

(2010) Miguel Sanz et al.   CURRENT OPINION IN ONCOLOGY

Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia

(2010) Celine Callens et al.   JOURNAL OF EXPERIMENTAL MEDICINE

MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation

(2009) M. E. Figueroa et al.   BLOOD

5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome - a systematic review and meta-analysis

(2009) R. Gurion et al.   HAEMATOLOGICA

Epidithiodiketopiperazines Block the Interaction between Hypoxia-inducible Factor-1α (HIF-1α) and p300 by a Zinc Ejection Mechanism

(2009) Kristina M. Cook et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes

(2009) Lanlan Shen et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization

(2009) S Goyama et al.   LEUKEMIA

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition

(2009) A Lakshmikuttyamma et al.   ONCOGENE

p21WAF1 gene promoter is epigenetically silenced by CTIP2 and SUV39H1

(2009) T Cherrier et al.   ONCOGENE

Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions

(2009) Bérengère Vire et al.   PLoS One

The Anticancer Agent Chaetocin Is a Competitive Substrate and Inhibitor of Thioredoxin Reductase

(2008) Jennifer D. Tibodeau et al.   ANTIOXIDANTS & REDOX SIGNALING

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

Aberrant DNA methylation is a dominant mechanism in MDS progression to AML

(2008) Y. Jiang et al.   BLOOD

H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias

(2008) Andrei V. Krivtsov et al.   CANCER CELL

EVI1 recruits the histone methyltransferase SUV39H1 for transcription repression

(2008) Francesca Cattaneo et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Arginine methylation regulates the p53 response

(2008) Martin Jansson et al.   NATURE CELL BIOLOGY

Chemical probes for histone-modifying enzymes

(2008) Philip A Cole   Nature Chemical Biology